Mereo BioPharma (MREO) Accumulated Depreciation (2022 - 2026)

Mereo BioPharma (MREO) has 5 years of Accumulated Depreciation data on file, last reported at $978000.0 in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $978000.0, down 3.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $978000.0 (down 3.74% YoY), and the FY2025 annual result was $1.1 million, up 14.33% from the prior year.
• Accumulated Depreciation retreated to $978000.0 in Q1 2026 per MREO's latest filing, from $1.1 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $1.1 million in Q2 2025 and troughed at $736000.0 in Q4 2022.
• A 5-year average of $945272.7 and a median of $964000.0 in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2025 and 2026: Accumulated Depreciation grew 26.57% in 2025, then declined 3.74% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $736000.0 in 2022, then climbed by 8.7% to $800000.0 in 2023, then climbed by 18.62% to $949000.0 in 2024, then gained by 14.33% to $1.1 million in 2025, then dropped by 9.86% to $978000.0 in 2026.
• Business Quant data shows MREO's Accumulated Depreciation at $978000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.0 million in Q3 2025.